The all-in-one platform to find and track your investments
Discover the features
Statistics
Market Cap
137 billion
PE Ratio
17.56 x
Beta (volatility)
0.43
Earnings Per Share
5.1
About
ISIN : FR0000120578
It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Heal
Price over 10 years
Performance Comparison
| Sanofi SA | |
|---|---|
| 1 year return |
+1 %
|
| 5 years return |
+55 %
|
Valuation (BETA)
For this company, we show you a quick help in graphical form that tells you if the stock looks overvalued, undervalued or fairly priced, and by how much. Stop paying too much for your shares.
Unlock valuation chart for this company
Dividend History
Uninter. Dividend
30 years +
Frequency
1x / year
Dividends in 2022
May
Dividends in 2021
May
May
Dividends in 2021
May
Forward Annual Amount
€3.33
Ex-dividend
5/6/2022
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
Valuation
| Price to Book | Payout ratio | PE Ratio | PEG Ratio |
|---|---|---|---|
| 1.61 | 65 % | 17.56 x | 1.63 |
| Price to Sales | Price / FCF | Enterprise Value Revenue |
|---|---|---|
| 3.5 | 13.28 | 2.90 |
News
Could This Vaccine Become Sanofi's Latest Blockbuster?
1/29/2023
Sanofi (SNY) Stock Sinks As Market Gains: What You Should Know
1/27/2023
Regeneron, Sanofi’s Dupixent is one step closer to approval for young children in Europe
1/27/2023
Deutsche Bank, UBS in Focus as Wall Street Sends Mixed Signals
1/27/2023
UPDATE 1-Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval
1/27/2023
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
1/27/2023
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
1/27/2023
Zacks.com featured highlights include Navios Maritime Partners, Hewlett Packard Enterprise, Aegon, Cowen and Sanofi
1/26/2023
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
1/25/2023
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
1/25/2023
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
1/25/2023
5 Value Stocks With Exciting EV-to-EBITDA Ratios to Own Now
1/25/2023
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy
•
Terms and Conditions
© Copyright 2020-2023 Epsylia OÜ - All rights reserved